Objective: To investigate the effects of changing from a medium (1.6 mg Cuad) to a low (0.7 mg Cuad) or a high (6.0 mgad) Cu intake on biochemical indices of bone turnover in healthy adult males. Design: A longitudinal intervention trial. Setting: The study was conducted at the Institute of Food Research, Norwich, UK. Subjects: Eleven healthy adult males aged 20 ± 59 y were recruited from Norwich Research Park. Intervention: Subjects were given medium (1.6 mgad), low (0.7 mgad) and high (6.0 mgad) intakes of Cu, in that order, over consecutive 8 week periods with a minimum of 4 week washout periods. On the last d of each dietary period fasting ®rst void urine and blood were collected. Results: Serum caeruloplasmin or Cu (indices of Cu status), serum osteocalcin (biomarker of bone formation), urinary creatinine (Cr) were unaffected by dietary Cu intake. Urinary PyraCr and DpyraCr (biomarkers of bone resorption) were signi®cantly increased (P`0.05) (by 30% and 25% respectively), when subjects were switched from the medium to the low Cu diet and were signi®cantly decreased (P`0.05) (by 30% and 22% respectively), when subjects were switched from the low to the high Cu diet. Conclusion: The ®ndings of the present study could have implications for bone health in individuals with marginal Cu intakes. Thus, further studies are warranted to better de®ne the relationship of marginal Cu intakes to bone health. Sponsorship: Funding from the European Commission and from the Ministry of Agriculture, Fisheries and Food.
Introduction
Copper has an important role in the metabolism of the skeleton where it performs a key catalytic function as a cofactor for lysyl oxidase (E.C. 1.4.3.13), a Cu-dependent extracellular amine oxidase which is important in the ®rst step of the maturation (crosslinking) of collagen to form stable ®brils (O'Dell, 1981; Tinker et al, 1988) . Studies in experimental animals have shown that Cu de®ciency can greatly reduce the activity of lysyl oxidase in bone (Siegel et al, 1970) and impair the crosslinking of collagen in the organic bone matrix (Robins et al, 1985; Farquharson et al, 1989; Jonas et al, 1993a) , leading to diminished tensile strength of bone (Jonas et al, 1993b) . Copper de®ciency during foetal and post-natal development has been shown to produce skeletal abnormalities and fragility in various species including the rat, chicken, pig, horse and rabbit (Hurley, 1981; Fell, 1987; Dolwett & Sorenson, 1988) . In humans, disorders of Cu de®ciency with skeletal defects, such as osteopenia, cupping and¯aring of metaphyses of long bones, submetaphyseal fracture, and spontaneous fractures, most frequently in the ribs, have been noted in Menkes' syndrome (Al-Rashid & Spangler, 1971; Seely et al, 1972; Ashkenazi et al, 1973) , an inherited disease of Cu de®ciency in young children where the gastrointestinal absorption of Cu is severely limited (Danks, 1987) . Skeletal defects such as osteoporosis, multiple fractures and a variety of bone development defects observed in pre-term infants, in which Cu nutritional status can be limited, have been reported to respond to oral supplementation with Cu which resulted in complete healing of fractures and improvement in the other bone defects (Allen et al, 1982; Patterson, 1990; Schmidt et al, 1991) .
There is some evidence for a role for Cu de®ciency in age-related osteoporosis. Serum Cu levels of 46 elderly patients with fractures of the femoral neck were reported to be signi®cantly lower than those of a group of controls matched for age and sex (Conlan et al, 1990) . A signi®cant positive correlation between serum Cu concentration and bone mineral density (BMD) at the lumbar spine has been reported in a cross-sectional study in postmenopausal women (Howard et al, 1990) . Eaton-Evans et al, (1996) have recently shown that Cu supplementation (3 mg per day for two y) reduced the rate of loss of BMD at the lumbar spine in women aged 45 ± 56 y suggesting that inadequate dietary Cu intake may be a contributory factor to agerelated bone loss in this population group.
Although mean daily Cu intakes of adults in Europe (1.0 ± 2.26 mg for males, 0.9 ± 1.79 mg for females, Van Dokkum, 1995) are greater than or close to the EU population reference intake (PRI) (1.1 mgad for adults; Report of the Scienti®c Committee for Food, 1993) , there may be signi®cant numbers of individuals with marginal Cu intakes. For example, Klevay et al, (1993) suggests that b 30% of diets in North America and Europe providè 1.0 mgad, the approximate amount of dietary Cu found to be insuf®cient in some short-term Cu depletion experiments in humans (Milne, 1998) and which the UK Department of Health considers to be de®cient (i.e. 0.8 ± 1.0 mg Cuad), as measured by a decline in superoxide dismutase (SOD) (EC. 1.15.1.1) and cytochrome-c oxidase (EC. 1.9.3.1) activities (DOH, 1991) . Recently, Turnlund et al, (1997) suggested that the average minimum dietary requirement for Cu in young men is between 0.4 and 0.8 mgad, based on the response of indices of Cu status to varying dietary Cu intakes, and above 0.8 mg Cuad, Cu depletion was not observed. It is unclear however, whether a dietary Cu intake in this range is optimal for bone metabolism.
The aims of the present study were to investigate the effects of changing from a medium Cu intake (1.6 mgad) to a diet low in Cu (0.7 mgad) or high in Cu (6.0 mgad) on biochemical indices of bone turnover in healthy adult males.
Methods

Subjects
Volunteers for the study were recruited locally through advertisements distributed at the Norwich Research Park. After clinical screening, 11 healthy adult males (mean age 30.9 (range 20 ± 59) y) were selected to participate in the study. Clinical screening included a full blood count (white blood cells, red blood cells, haemoglobin, haematocrit, platelet concentration) and a general pro®le (Na, K, bicarbonate, urea, creatinine, total bilirubin, total protein, albumin, globulin, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, g-glutamyltransferase, Ca, P, total cholesterol, glucose). Subjects were only accepted onto the study if the test results were found to be within normal ranges. All subjects were without any history of bone or articular disease, and with no intake of medicine that could affect bone or cartilage metabolism. Additional exclusion criteria included chronic illness, smoking or taking nutritional supplements. The mean height, weight and body mass index (BMI) for the subjects are provided in Table 1 .
Ethical considerations
Before participation in this study, all subjects signed an informed consent document approved by the Institute of Food Research Human Research Ethics Committee.
Experimental design
The study consisted of a longitudinal intervention trial of the effect of low, medium and high intakes of Cu on biochemical markers of bone turnover in healthy adult males.
The trial was designed so that all subjects were given medium (1.6 mgad), low (0.7 mgad) and high (6.0 mgad) intakes of Cu, in that order, over consecutive 8 week periods with a minimum of 4 week washout periods. This experimental design was similar to that used in other human metabolic studies on Cu (Turnlund et al, 1989 (Turnlund et al, , 1990 (Turnlund et al, , 1997 Milne et al, 1990; Kelley et al, 1995) and was chosen to minimise possible carry-over effects of changing dietary Cu intakes between dietary periods. During the study, the subjects lived in a residential metabolic research unit at the Institute of Food Research, Norwich for the three 8 week periods of dietary manipulation but were allowed to return home for the intervening washout periods. Subjects were staggered into manageable batches which were taken at different times throughout a three year period. A 7 d rotating low Cu menu was formulated and analysed for Cu content. This low Cu diet (0.7 mgad) was fed throughout the three dietary periods and was supplemented to the appropriate level of Cu (as a CuSO 4 solution (Analar grade anhydrous copper (II) sulphate (BDH Ltd, Poole, Dorset, UK) dissolved in de-mineralised water (Elga Ltd, High Wycombe, UK)) taken with a meal) to achieve the medium (1.6 mgad) and high (6.0 mgad) Cu intakes. All other nutrients met with the UK Reference Nutrient Intakes (Department of Health, 1991) . During the three 8 week dietary periods, subjects were instructed to collect a fasting ®rst void urine sample between 0700 ± 0900 h on the morning of d 42. In addition, after an overnight fast, a blood sample (10 ml) was also taken at 0900 h on the same day.
Diets
Subjects were fed a constant weighed diet of conventional foods that was low in Cu (0.70 mgad, 0.267 AE 0.011 mgakcal, by analysis) on a 7 d menu rotation. The low Cu diet was achieved by avoiding Cu-rich foods such as organ meats (liver and kidney), oysters, shrimp, nuts, wheat bread and whole-wheat bread (detailed menu available from the authors). The diet was planned to contain at least the recommended level (Department of Health, 1991) of all known nutrients except Cu. This low Cu diet was fed throughout the three dietary metabolic periods and was supplemented to the appropriate level of Cu (as a CuSO 4 solution taken with a meal) to achieve the medium (1.6 mgad) and high (6.0 mgad) Cu intakes.
Collection and preparation of samples Subjects were supplied with suitable collection containers for urine samples and asked to collect a fasting ®rst void morning urine sample between 0700 ± 0900 h on d 42 of each dietary period. Portions of urine were stored at 720 C from the morning of collection until required for analysis. Blood was collected by venepuncture into additive-free vacutainer tubes which was processed to serum and which was either immediately stored at 770 C until required for osteocalcin analysis or was sent to the Experimental techniques Urinary pyridinoline and deoxypyridinoline. The urine samples from each individual were analysed separately in triplicate using a three-step procedure. Urine was ®rst hydrolysed with an equal volume of 12 M-HCl at 110 C for 18 h, the crosslinks were then extracted by CF1 cellulose chromatography with the use of an internal standard (acetylated pyridinoline, MetraBiosystems Ltd, Wheatley, UK) and were measured using a reversed-phase HPLC method with¯uorescence detection (Colwell et al, 1993) . The acetylated pyridinoline was used in accordance with the method as described by Calabresi et al, (1994) and Robins et al, (1994) . The crosslinks content of urines were quantitated by external standardisation using a commercially available pyridinolineadeoxypyridinoline HPLC calibrator (MetraBiosystems Ltd, Wheatley, UK). The intraassay coef®cient of variation (CV) for pyridinoline (Pyr) and deoxypyridinoline (Dpyr) measured as the variation between 10 chromatograms obtained between column regenerations as described by Colwell et al, (1993) were 6% and 7%, respectively. Interassay variation was avoided by analysing all samples from an individual in the same run.
Urinary creatinine. Fresh daily urine samples were analysed in duplicate by a colorimetric procedure using a diagnostic kit (Catalogue No. 124, 192 ; Boehringer Mannheim GmbH, Mannheim, Germany). The intra-and interassy CV were 3.4% and 6.3%, respectively. Serum osteocalcin. Serum osteocalcin levels were measured using an enzyme-linked immunosorbent assay (ELISA) (BRI-Diagnostics, Dublin 9, Ireland). The intraassay CV was 10.2%. Interassy variation was avoided by analysing all samples from an individual in the same run. Serum copper. Cu was analysed in duplicate in serum samples by atomic absorption spectrophotometry (Philips Atomic Absorption Spectrophotometer, Model PU 9200, Philips, Cambridge, UK). The inter-assay CV was 6.4%.
Serum total caeruloplasmin. Serum total Cp protein concentration was determined by immunoturbidimetry (DAKO, Glostrup, Denmark). The inter-assay CV was 10.0%.
Statistical analysis
Data are presented as means with their standard deviations (s.d.). Data for all variables were normally distributed and allowed for parametric tests of signi®cance. Changes in the putative indices of Cu status and in the biochemical indices of bone turnover during the medium, low and high dietary Cu periods were analysed by the repeated measures ANOVA. Where a signi®cant F value was found, the least signi®cant difference (LSD) test for multiple means was used as a post hoc test to determine which treatment means differed (Steel & Torrie, 1980) .
Results
Data on putative indices of Cu status at the end of wk 6 of each dietary metabolic period are shown in Table 2 . Caeruloplasmin (Cp) and Cu concentrations in serum were unaffected by dietary Cu intake.
The effects of reducing Cu intake from a medium (1.6 mgad) to a low (0.7 mgad) level, and subsequently increasing Cu intake from the low to a high level (6.0 mgad), each for 8 weeks on serum and urinary biochemical indices of bone turnover are shown in Table 2 . Urinary creatinine (Cr) concentration was unaffected by dietary Cu intake. There was a signi®cant increase (P`0.05) in urinary PyraCr excretion (30%) and urinary DpyraCr excretion (25%) when subjects were switched from the medium to the low Cu diet. Furthermore, there was a signi®cant decrease (P`0.05) in urinary PyraCr excretion (30%) and urinary DpyraCr excretion (22%) when subjects were switched from the low to the high Cu diet. The ratio of Pyr to Dpyr in urine was unaffected by dietary Cu intake.
There were no signi®cant differences in serum osteocalcin, a marker of bone formation, between the three dietary periods. {A repeated measures ANOVA model was used to determine the effect of the three dietary Cu intakes on each biochemical index. *Mean value was signi®cantly different from that during the medium or high dietary Cu periods using the least signi®cant difference (LSD) test (P`0.05).
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Discussion
The present study in healthy adult males showed that two widely used putative indices of Cu status (serum Cu and Cp concentration) were unaffected by either dietary depletion or repletion of Cu. This is in agreement with the ®ndings of other studies which examined the in¯uence of varying dietary Cu intake (in the same range as that used in the present study) on indices of Cu status in men (Milne et al, 1990; Turnlund et al, 1990) . Turnlund et al, (1990) , for example, found that several putative indices of Cu status (including plasma Cu and Cp) were unaffected when young men were switched from an`adequate' Cu diet (1.68 mgad) to a low Cu diet (0.79 mgad), and subsequently, from the low to a high Cu diet (7.53 mgad) for 24, 42 and 24 d, respectively. Milne et al, (1990) showed that there were no signi®cant changes in several putative indices of Cu status in young men who were switched from a usual dietary Cu intake of 1.29 mg Cuad to a low Cu diet (0.89 mgad), and subsequently, to a high Cu diet (5.05 mgad) for periods ranging from 105 to 120 d. Turnlund et al, (1997) recently reported that in men who were placed on dietary Cu intakes of 0.66, 0.38 and 2.49 mgad, in that order, for 24, 42 and 24 d, respectively, plasma Cu, Cp and urinary Cu were reduced during the period of lowest Cu intake (which was substantially lower than that used in the present study i.e. 0.7 mg Cuad) and increased in response to Cu repletion. Therefore, it appears that adaptive mechanisms such as increased ef®ciency of intestinal Cu absorption and reduced excretion of endogenous Cu, help to prevent Cu depletion when dietary Cu is restricted to around 0.7 to 0.8 mgad, as reported by Turnlund et al, (1990) , but that adaptive capacity is exceeded at dietary intakes of around 0.4 mgad over a period of several weeks. Turnlund et al, (1997) have suggested that the minimum dietary Cu requirement is between 0.4 and 0.8 mgad.
Despite the observed lack of effect on indices of Cu status, switching from a medium (1.6 mgad) to low (0.7 mgad) intake of dietary Cu caused a signi®cant increase in urinary excretion of both Pyr (30%) and Dpyr (25%) in the present study. Urinary Pyr and Dpyr are sensitive and speci®c biochemical markers of bone resorption (Eyre, 1992; Robins & New, 1997) and the increased excretion of these biomarkers is indicative of increased rate of bone resorption. The increased rate of urinary pyridinium crosslink excretion was reversed during the subsequent 8 week period of dietary Cu repletion (that is, high Cu diet). To our knowledge, there is no other report in the literature in which the in¯uence of dietary Cu intake on urinary pyridinium crosslink excretion was examined in humans. However, there is some evidence that Cu de®ciency in¯uences bone resorption. An increased rate of bone resorption has been suggested as one explanation for the reduced bone mass observed in Cu-de®cient rats (Strause et al, 1986) . Furthermore, studies carried out in vitro have shown that Cu reduces active bone resorption, as measured by release of 45 Ca or hydroxyproline into the bathing medium from cultured explanted 45 Ca-labelled mouse calvaria bone grown in medium with or without the addition of Cu (Wilson et al, 1981; Katz et al, 1984) . The concentration of Cu used in media in these in vitro studies corresponded to physiological concentrations of Cu found in experimental mice.
Although the present study was of relatively short duration it does demonstrate a response to dietary Cu restriction of urinary pyridinium crosslink excretion which may be considered an early indicator of increased bone turnover (Eyre, 1992) which, if sustained, would result in a measurable reduction in bone mass over time (Heaney, 1994) . Recently, it has been recognised that an increased rate of bone turnover in adults may be a risk factor for fracture (Riggs et al, 1996) , because it exacerbates bone loss (Hansen et al, 1991) . High rates of bone turnover are also associated with a disruption of the trabecular network leading to a loss of connectivity which is not necessarily re¯ected in a decrease of bone mass (Par®tt, 1984) . While there was no effect of dietary Cu restriction on serum osteocalcin, a biomarker of bone formation, in the present study, this can be explained by the short duration of the study since bone formation, although coupled to bone resorption, is separated in time by approximately 6 ± 7 weeks (Eriksen et al, 1984) .
It is unclear from this 8 week study how long the increased rate of bone resorption is sustained, and the possibility of long-term adaptation cannot be excluded. However, an effect of Cu on bone turnover may explain the observation of Eaton-Evans et al, (1996) who reported that Cu supplementation with an additional 3 mgad for 2 y in middle-aged women (45 ± 56 y) with a usual dietary Cu intake of around 1 mgad, lead to a reduced rate of loss of BMD at the lumbar spine.
The underlying mechanisms for the osteoporotic-like lesions observed in bone in Cu de®ciency disorders in animal species and humans are not understood but such abnormalities are generally considered to be due to defective bone formation secondary to reduced lysyl oxidase activity (Danks, 1988) . However, reduced lysyl oxidase activity with consequent reduction in collagen crosslinking does not readily explain the increased excretion of pyridinium crosslinks observed in the present study. Our results, taken together with the evidence from in vitro studies (Wilson et al, 1981; Katz et al, 1984) suggests that increased bone resorption may also contribute to the demineralisation of bone seen in Cu de®ciency. EatonEvans et al, (1996) have suggested that reduced activity of other Cu ± dependent enzymes for example, superoxide dismutase and cytochrome c oxidase, could be involved in the abnormalities of bone seen in Cu de®ciency.
Conclusion
The ®ndings of the present study could have implications for bone health in individuals with marginal Cu intakes. Therefore, further studies are warranted to better de®ne the relationship of marginal Cu intakes to bone health in different life-stage groups.
